All publications
Selecting efficient pharmaceutical binder for developing robust extended-release matrices of Compritol® 888 ATO prepared using wet granulation technique: Part 1 Studying impact on granule & tablet properties
CRS Annual Meeting - virtual - Jul 2021
GELUCIRE® 4414 for type IV lipid based formulations and their in vitro in vivo performance evaluation
AAPS PharmSci360 – Philadelphia (USA) - 2021
In this study, Gelucire® 44/14 in type IV lipid-based formulation has been evaluated to increase the solubility and in vivo performance of ticagrelor.
Solid lipid nanocarriers to increase oral bioavailability of the peptide Leuprolide
PBP World Meeting - 2021
Formulation forum – A Quick Approach for Evaluation of Drug-Excipient Compatibility: Case of Acetylsalicylic Acid
Drug Development & Delivery - 2021
In this study, the authors monitor acetylsalicylic acid (ASA) hydrolysis in different formulations using UPLC and TAM with the objective of comparing these methods for agreement, speed, and efficiency in predicting drug stability. In parallel, we assess the impact of the excipient choices on the stability of the ASA.
Lipid excipients to unlock oral bioavailability issues
American Pharmaceutical Review - Feb 2021
Table of content:
Introduction
Chapter I : Lipids, reliable partners to enhance oral bioavailability of poorly water-soluble drugs
Chapter II : Lipids to enhance the intestinal permeability of poorly permeable drugs
Chapter III : Targeting lymphatic absorption with appropriate lipid excipients selection
Chapter IV : Mitigating food effect with lipid-based formulations
Chapter V : Gattefossé range of functional excipients
for oral bioavailability enhancement
Solid lipid Nanocarriers diffuse effectively through mucus and enter intestinal cells – but where is my peptide?
International Journal of Pharmaceutics, Volume 586, 119581 https://doi.org/10.1016/j.ijpharm.2020.119581 - Aug 2020
This study aimed to evaluate the potential of Hydrophobic Ion Pairing combined with Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) to improve peptide transport across the intestinal border using Caco-2 cell monolayers (enterocyte-like model) and Caco-2/HT29-MTX co-cultured monolayers (mucin-secreting model).
This study showed that hydrophobic ion pairing enabled high encapsulation efficiency of peptide in SLN and NLC. The lipid-based nanocarriers were highly internalized by Caco-2 cell monolayers and were able to cross the mucus barrier (Caco-2/HT29-MTX cell model). However, the peptide intestinal transport was limited by an extensive release from the carriers.
Solid lipid nanocarrier development toolbox for increasing oral bioavailability of API
American Pharma Review, May-June 2020 issue, pp 69-75 - May 2020
In this comprehensive article, the author describes the latest tools available to develop solid lipid nanoparticles: how to prepare and characterize solid lipid nanoparticles, how to evaluate encapsulation efficiency and intestinal permebility.
DOs and DON’Ts for developing successful SEDDS formulations to enhance API bioavailability
Tablets&Capsules, p.37-39 - Apr 2020
A proof-of-concept for developing oral lipidized peptide Nanostructured Lipid Carrier formulations
Journal of Drug Delivery Science and Technology, Volume 54, 101394 https://doi.org/10.1016/j.jddst.2019.101394 - Dec 2019
A proof-of-concept for developing oral lipidized peptide Nanostructured Lipid Carrier formulations